Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab

Abstract

Real-world data on treatment patterns associated with use of interleukin-17A inhibitors in psoriasis are lacking. To compare treatment patterns between ixekizumab or secukinumab users in clinical practice. A retrospective cohort study included patients with psoriasis aged ≥18years treated with ixekizumab or secukinumab between March 1, 2016, and May 31, 2018 in IBM MarketScan (IBM Corp, Armonk, NY) databases. Inverse probability of treatment weighting and multivariable models were used to address cohort imbalances and estimate the risks of nonpersistence (60-day gap), discontinuation (≥90-day gap), switching, and the odds of adherence. The study monitored 645 ixekizumab users for 13.7months and 1152 secukinumab users for 16.3months. Ixekizumab users showed higher persistence rate (54.8% vs 45.1%, P<.001) and lower discontinuation rate (37.8% vs 47.5%, P<.001) than secukinumab. After multivariable adjustment, ixekizumab users had lower risks of nonpersistence (hazard ratio, 0.82; 95% confidence interval, 0.71-0.95) and discontinuation (hazard ratio, 0.82; 95% confidence interval, 0.70-0.96), and higher odds of high adherence to treatment measured by a medication possession ratio ≥80% (hazard ratio, 1.31; 95% confidence interval, 1.07-1.60). The risk of switching was similar between cohorts. Disease severity and clinical outcomes were unavailable. Ixekizumab users demonstrated longer drug persistence, lower discontinuation rate and risk of discontinuation, higher likelihood of adherence, and similar risk of switching compared with secukinumab users in clinical practices.